Gram-negative bacteria are a large group of microorganisms classified by how they respond to a laboratory staining technique called the Gram stain. They appear pink or red under a microscope, in contrast to gram-positive bacteria, which stain purple or blue. This color difference reflects a fundamental difference in cell structure that has real consequences for human health: gram-negative bacteria are harder to kill with antibiotics, and several species rank among the most dangerous drug-resistant pathogens in the world.
How the Gram Stain Works
The Gram stain, developed in the 1880s, is one of the first tests run when a lab needs to identify an unknown bacterium. The process starts by applying a purple dye (crystal violet) to a bacterial sample on a glass slide. At this stage, all bacteria turn purple. A solvent is then added, and this is where the two groups diverge. Gram-negative bacteria have a high lipid (fat) content in their outer structure. The solvent dissolves that lipid layer, washing the purple dye out of the cell. A second dye, a pink counterstain, is then applied. Gram-negative bacteria pick up this pink color, while gram-positive bacteria retain the original purple.
The test takes minutes to perform and immediately narrows down the possible identity of an infection, guiding early treatment decisions before more specific tests come back.
What Makes Their Cell Wall Different
The reason gram-negative bacteria lose the purple dye comes down to their unique double-membrane structure. All bacteria have a cell wall containing a mesh-like material called peptidoglycan, which gives the cell its shape. In gram-positive bacteria, this layer is thick, roughly 30 to 100 nanometers, and it traps the purple dye effectively. Gram-negative bacteria have a peptidoglycan layer only a few nanometers thick, sometimes just one or two layers deep.
What gram-negative bacteria have instead is an additional outer membrane that gram-positive bacteria lack entirely. This outer membrane contains a molecule called lipopolysaccharide (LPS) on its surface. LPS serves as a powerful shield, giving the bacterium unusual permeability properties that block many toxic compounds from entering the cell. This includes a wide range of clinically useful antibiotics. The outer membrane is also the reason these bacteria provoke such strong immune responses during serious infections. When gram-negative bacteria die and break apart, LPS fragments (sometimes called endotoxin) flood into the bloodstream and can trigger severe inflammation, fever, and in extreme cases, septic shock.
Common Gram-Negative Bacteria
Many gram-negative species live harmlessly in the human gut, on the skin, or in the environment. Problems arise when they end up in the wrong place or when the immune system is compromised. The CDC highlights several gram-negative bacteria of particular concern:
- E. coli: the most common cause of urinary tract infections and a frequent source of foodborne illness. Most strains are harmless residents of the intestine, but pathogenic strains can cause severe diarrhea, kidney damage, and bloodstream infections.
- Klebsiella: often responsible for pneumonia and bloodstream infections, particularly in hospital patients on ventilators or with weakened immune systems.
- Pseudomonas aeruginosa: thrives in moist environments and is notorious for infecting surgical wounds, burn injuries, and the lungs of people with cystic fibrosis. It is naturally resistant to many antibiotics.
- Acinetobacter: primarily a hospital-acquired pathogen that can survive on surfaces for extended periods, causing wound infections and pneumonia in intensive care settings.
Other notable gram-negative pathogens include Salmonella (a leading cause of food poisoning), Shigella (which causes dysentery), and Neisseria gonorrhoeae (the bacterium behind gonorrhea).
Infections They Cause
Gram-negative bacteria are responsible for a wide spectrum of infections. Urinary tract infections are the most common in the general population, with E. coli behind roughly 80% of cases. Pneumonia caused by gram-negative species tends to occur in hospitalized or immunocompromised patients rather than otherwise healthy people. Bloodstream infections (bacteremia) can develop when bacteria from a localized infection, such as a UTI or a wound, spread into the blood. This can escalate to sepsis, a life-threatening condition where the body’s immune response spirals out of control.
Surgical site infections, meningitis, and gastrointestinal infections round out the list. In hospitals, gram-negative bacteria are a leading cause of healthcare-associated infections, partly because they colonize medical equipment like catheters and ventilator tubing.
Why They’re So Hard to Treat
Gram-negative bacteria are inherently more difficult to treat than gram-positive species, and the gap is widening. Their natural defenses start with that outer membrane, which physically blocks many antibiotic molecules from reaching their targets inside the cell. Beyond this built-in barrier, gram-negative bacteria deploy several active resistance strategies.
One major mechanism involves enzymes called beta-lactamases that chew up antibiotics before they can work. These enzymes target penicillins, cephalosporins, and even carbapenems, which are often considered last-resort drugs. Some bacteria produce extended-spectrum versions of these enzymes that can neutralize nearly every antibiotic in the beta-lactam family.
Another strategy involves efflux pumps, which are molecular machines embedded in the bacterial membranes that actively pump antibiotics back out of the cell before they reach lethal concentrations. Some efflux pumps are broad-spectrum, ejecting multiple classes of antibiotics at once. A third mechanism involves mutations that alter the tiny pores (porins) in the outer membrane, narrowing or closing the channels that antibiotics use to enter.
What makes the situation especially concerning is that bacteria can share resistance genes with each other, even across different species. A resistance gene carried on a small piece of mobile DNA can jump from one bacterium to another, spreading drug resistance through a hospital or community rapidly.
Treatment Options
Doctors rely on several antibiotic classes to fight gram-negative infections. Cephalosporins, carbapenems, fluoroquinolones, aminoglycosides, and tetracyclines all have activity against various gram-negative species. Because resistance patterns vary widely, effective treatment almost always depends on lab testing to determine which specific antibiotics will work against the strain causing the infection.
In recent years, new combination drugs have been developed that pair an antibiotic with a compound that disables the bacterium’s beta-lactamase enzymes. These combinations can restore the effectiveness of antibiotics that the bacteria had learned to destroy. Several of these combination drugs were approved in the 2010s specifically to address the growing threat of multidrug-resistant gram-negative infections.
A Global Health Priority
The World Health Organization maintains a priority pathogens list to guide research and public health strategy around antibiotic resistance. Gram-negative bacteria resistant to last-resort antibiotics rank among the most critical threats on that list. The 2024 update specifically flags drug-resistant strains of Pseudomonas aeruginosa, Acinetobacter, and members of the Enterobacteriaceae family (which includes E. coli and Klebsiella) as urgent priorities for new antibiotic development.
The concern is straightforward: if resistance continues to outpace the development of new drugs, infections that are currently treatable could become fatal. This is already happening in some healthcare settings, where pan-resistant gram-negative bacteria, strains resistant to every available antibiotic, have been documented. Infection control measures like hand hygiene, careful use of antibiotics, and hospital surveillance programs remain the front line of defense against the spread of these organisms.